{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:44:26Z","timestamp":1786113866418,"version":"build-2736575974"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"AIRC Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Open Science"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.euros.2026.06.004","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T12:17:38Z","timestamp":1783081058000},"page":"77-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The ITALIC-RCC: A Randomized Trial on Clinical and Humoral Impact of Primary Tumor Ablation by Surgery or Radiotherapy in Metastatic Renal Cell Carcinoma Treated with Checkpoint Inhibitors"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1750-2117","authenticated-orcid":false,"given":"Roberto","family":"Iacovelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Ciccarese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Arduini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Tagliaferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Minervini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Ficarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camillo","family":"Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Calabr\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Zucali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Troisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Francolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio Giuseppe","family":"Morganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Franzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara Alicja","family":"Jereczek-Fossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo Cesare","family":"Maria Rocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euros.2026.06.004_b0005","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J Clin"},{"key":"10.1016\/j.euros.2026.06.004_b0010","first-page":"e217","article-title":"Immune phenotype\u2013genotype associations in primary and metastatic sites in clear cell renal cell carcinoma","volume":"22","author":"Tian","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euros.2026.06.004_b0015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1464-410X.1994.tb16538.x","article-title":"Immunological parameters in peripheral blood of patients with renal cell carcinoma before and after nephrectomy","volume":"74","author":"Dadian","year":"1994","journal-title":"Br J Urol"},{"key":"10.1016\/j.euros.2026.06.004_b0020","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000019821","article-title":"Pro-inflammatory and T cell inhibitory cytokines are secreted at high levels in tumor cell cultures of human renal cell carcinoma","volume":"35","author":"Lahn","year":"1999","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.06.004_b0025","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1097\/01.ju.0000110610.61545.ae","article-title":"Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis","volume":"171","author":"Flanigan","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2026.06.004_b0030","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1803675","article-title":"Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma","volume":"379","author":"M\u00e9jean","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2026.06.004_b0035","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamaoncol.2018.5543","article-title":"Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial","volume":"5","author":"Bex","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euros.2026.06.004_b0040","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.eururo.2021.06.009","article-title":"Sunitinib alone or after nephrectomy for patients with metastatic renal cell carcinoma: is there still a role for cytoreductive nephrectomy?","volume":"80","author":"M\u00e9jean","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.06.004_b0045","unstructured":"EAU guidelines for Renal Cell Carcinoma Edn. Presented at the EAU Annual Congress Paris 2024. ISBN 978-94-92671-23-3."},{"key":"10.1016\/j.euros.2026.06.004_b0050","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S1470-2045(22)00656-8","article-title":"5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney)","volume":"23","author":"Siva","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euros.2026.06.004_b0055","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.euf.2019.06.002","article-title":"The emerging role of stereotactic ablative radiotherapy for primary renal cell carcinoma: a systematic review and meta-analysis","volume":"5","author":"Correa","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euros.2026.06.004_b0060","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S1470-2045(24)00020-2","article-title":"Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial","volume":"25","author":"Siva","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euros.2026.06.004_b0065","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(23)00513-2","article-title":"Stereotactic body radiotherapy for primary renal cell carcinoma: a systematic review and practice guideline from the International Society of Stereotactic Radiosurgery (ISRS)","volume":"25","author":"Siva","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euros.2026.06.004_b0070","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euros.2026.06.004_b0075","unstructured":"National Cancer Institute. Common terminology criteria for adverse events (CTCAE). v5.0. https:\/\/www.cancer.gov\/research\/resources\/resource\/210. Accessed March 2nd, 2026."},{"key":"10.1016\/j.euros.2026.06.004_b0080","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","article-title":"The Clavien-Dindo classification of surgical complications: five-year experience","volume":"250","author":"Clavien","year":"2009","journal-title":"Ann Surg"},{"key":"10.1016\/j.euros.2026.06.004_b0085","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s10353-018-0551-z","article-title":"Experiences with the standardized classification of surgical complications (Clavien-Dindo) in general surgery patients","volume":"50","author":"Bolliger","year":"2018","journal-title":"Eur Surg"}],"container-title":["European Urology Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168326006361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168326006361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T19:59:05Z","timestamp":1785959945000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666168326006361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":17,"alternative-id":["S2666168326006361"],"URL":"https:\/\/doi.org\/10.1016\/j.euros.2026.06.004","relation":{},"ISSN":["2666-1683"],"issn-type":[{"value":"2666-1683","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The ITALIC-RCC: A Randomized Trial on Clinical and Humoral Impact of Primary Tumor Ablation by Surgery or Radiotherapy in Metastatic Renal Cell Carcinoma Treated with Checkpoint Inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Urology Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euros.2026.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}